Achilles Therapeutics (ACHL) Stock Price, News & Analysis

Company Overview

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $1.48 to $1.48
• 50-Day Range: $1.37 to $1.49
• 52-Week Range: $0.63 to $1.51
• Volume: N/A
• Average Volume: 569,550 shs
• Market Capitalization: $60.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACHL Stock Analysis - Frequently Asked Questions

How have ACHL shares performed this year?

Achilles Therapeutics' stock was trading at $1.14 at the beginning of the year. Since then, ACHL shares have increased by 29.8% and is now trading at $1.48.
View the best growth stocks for 2025 here.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) posted its earnings results on Wednesday, August, 14th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41).

When did Achilles Therapeutics IPO?

Achilles Therapeutics (ACHL) raised $176 million in an initial public offering (IPO) on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Achilles Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Digital Turbine (APPS), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 4/26/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACHL
• CIK: 1830749
• Web: www.achillestx.com
• Phone: 44-0-20-8154-4600
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-69,670,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.45%
• Return on Assets: -47.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.04
• Quick Ratio: 6.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.49 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 41,100,000
• Free Float: 38,889,000
• Market Cap: $60.83 million
• Optionable: Not Optionable
• Beta: 1.25